Evidence map›Paper›PMID 42750795›Full record

ArticlePublic health challenges2026

The Terminator-A Blood Test for Early Detection of 50 Cancers.

Abraham Fessehaye Sium, Don Eliseo Lucero-Prisno

Abstract read
In one paragraph

Article in Public health challenges, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Abraham Fessehaye SiumDepartment of Obstetrics and Gynecology St Paul's Hospital Millennium Medical College Addis Ababa Ethiopia.ORCID https://orcid.org/0000-0001-5812-0804
Don Eliseo Lucero-PrisnoDepartment of Global Health and Development, Faculty of Public Health and Policy London School of Hygiene and Tropical Medicine London UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Globally, cancer remains the second leading cause of premature death. Although there are existing cancer screening programs for early detection of some of the cancers, screening remains ineffective and at times difficult for the deadliest ones, as a result of which patients present in advanced stages with guarded prognoses. Recently, promising results have been found in the largest interventional study (PATHFINDER2) of Galleri test (a multi-cancer early detection [MCED] test). In this article, we dive below this headline and discuss its implications for actual clinical care and what it may contribute in addressing cancer as a top public health problem.

Indexed as

cancercancer diagnosiscancer screeningGalleri testglobal healthmortality

Identifiers

PMID42750795
PMCPMC13578097

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.